Teladoc Health (TDOC) Cash & Equivalents (2013 - 2026)

Teladoc Health has disclosed Cash & Equivalents across 14 years of filings, most recently posting $750.7 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $750.7 million, down 37.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $750.7 million (down 37.09% YoY), and the FY2025 annual result was $781.1 million, down 39.84% from the prior year.
• Cash & Equivalents came in at $750.7 million for Q1 2026 at Teladoc Health, down from $781.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q4 2024 to a low of $679.6 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $918.2 million (2022), against an average of $968.8 million.
• Across the five-year window, Cash & Equivalents advanced 23.56% in 2024 and plunged 41.61% in 2025, its largest moves.
• Teladoc Health's Cash & Equivalents stood at $918.2 million in 2022, then increased by 22.38% to $1.1 billion in 2023, then advanced by 15.54% to $1.3 billion in 2024, then plunged by 39.84% to $781.1 million in 2025, then declined by 3.89% to $750.7 million in 2026.
• The last three Cash & Equivalents figures came in at $750.7 million (Q1 2026), $781.1 million (Q4 2025), and $726.2 million (Q3 2025), per Business Quant data.